发明公开
EP1131096A1 CHIMERIC ANTI-CD20 ANTIBODY TREATMENT OF PATIENTS RECEIVING BMT OR PBSC TRANSPLANTS
有权
的患者治疗骨髓移植或移植的外周血干细胞抗CD20抗体GET
- 专利标题： CHIMERIC ANTI-CD20 ANTIBODY TREATMENT OF PATIENTS RECEIVING BMT OR PBSC TRANSPLANTS
- 专利标题（中）： 的患者治疗骨髓移植或移植的外周血干细胞抗CD20抗体GET
-
申请号： EP99958649.8申请日： 1999-11-09
-
公开(公告)号： EP1131096A1公开(公告)日： 2001-09-12
- 发明人: GRILLO-LOPEZ, Antonio, J. , LEONARD, John, E.
- 申请人： IDEC PHARMACEUTICALS CORPORATION
- 申请人地址： 11011 Torreyana Road San Diego, CA 92121-1104 US
- 专利权人： IDEC PHARMACEUTICALS CORPORATION
- 当前专利权人： IDEC PHARMACEUTICALS CORPORATION
- 当前专利权人地址： 11011 Torreyana Road San Diego, CA 92121-1104 US
- 代理机构： Daniels, Jeffrey Nicholas
- 优先权： US107657P 19981109
- 国际公布： WO0027433 20000518
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; A61K39/00 ; A01N63/00 ; A01N1/02 ; A01N1/00
摘要：
The use of a chimeric anti-CD20 antibody, RITUXAN®, as an in vivo or in vitro purging agent, of patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related malignancies, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
公开/授权文献
信息查询
